Drug Type Natural Killer Cell Therapies |
Synonyms NK 042, NK042 |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Multiple Sclerosis, Primary Progressive | Phase 1 | - | 01 May 2026 | |
| Multiple Sclerosis, Relapsing-Remitting | Phase 1 | - | 01 May 2026 | |
| Multiple Sclerosis, Secondary Progressive | Phase 1 | - | 01 May 2026 | |
| Lupus Nephritis | Phase 1 | China | 19 Feb 2025 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | China | 07 Feb 2025 |





